The ganglioside GD2 as a circulating tumor biomarker for neuroblastoma
Pediatric Blood & Cancer2019Vol. 67(1), pp. e28031–e28031
Citations Over TimeTop 10% of 2019 papers
Frank M. Balis, Christine M. Busch, Ami V. Desai, Emily Hibbitts, Arlene Naranjo, Rochelle Bagatell, Meredith S. Irwin, Elizabeth Fox
Abstract
Circulating GD2 appears to be a specific and sensitive tumor biomarker for high-risk/high-stage neuroblastoma and may prove to be clinically useful as a diagnostic or prognostic circulating tumor biomarker. GD2 will be measured prospectively and longitudinally in children enrolled on a high-risk neuroblastoma treatment trial to assess its ability to measure response to treatment and predict survival.
Related Papers
- → Vasoactive intestinal peptide producing neuroblastoma(1982)26 cited
- → Neuroblastoma and Related Tumors(2005)9 cited
- → Complete maturation of neuroblastoma with bone metastases in documented stages(1975)24 cited
- → Neuroblastoma and Other Adrenal Tumors(2008)2 cited
- → Neuroblastoma and Neuroblastic Tumors(2018)